TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03818672
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 550 MG BID
Study: NCT00313820
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
Study: NCT00265889
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
Study: NCT00265889
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg, IV
Study: NCT00265889
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
Study: NCT00860379
Drug: Selenium1
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ug/kg
Study: NCT00860379
Drug: Selenium2
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ug/kg
Study: NCT03519854
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.
Study: NCT01515748
Drug: Docetaxel (XRP6976)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study: NCT01515748
Drug: Oxaliplatin (SR96669)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study: NCT01458197
Drug: Tarafenacin 0.2 mg
DrugBank: Tarafenacin (DB18810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, qd, 12 weeks
Study: NCT01458197
Drug: Tarafenacin 0.4 mg
DrugBank: Tarafenacin (DB18810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, qd, 12 weeks
Study: NCT00501254
Drug: Slow release acetyl salicylic acid
Normalized name: acetyl salicylate
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03345498
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
Study: NCT00416182
Drug: Pulmozyme (dornase alfa)
Normalized name: dornase alfa Inhalation Solution [Pulmozyme]
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
Study: NCT02535104
Drug: Ranpirnase
Normalized name: Ranpirnase
DrugBank: Ranpirnase (DB04950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application by subject
Study: NCT04944641
Drug: routine and proper antiepileptic drugs
Normalized name: mometasone Drug Implant [Propel]
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine and proper antiepileptic drugs
Study: NCT00769548
Drug: flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug used for TAS.
Study: NCT00769548
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug used for TAS.
Study: NCT01245205
Drug: Akt inhibitor MK2206
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00541450
Drug: Comparator: sitagliptin phosphate (sitagliptin)
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
Study: NCT00541450
Drug: sitagliptin phosphate (+) metformin hydrochloride
Normalized name: metformin / sitagliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
Study: NCT00541450
Drug: Comparator: pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
Study: NCT00541450
Drug: Matching placebo to pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks.
Study: NCT00541450
Drug: Matching placebo to sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
Study: NCT01550458
Drug: mibefradil
Normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
Study: NCT02262533
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02262533
Drug: Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03511833
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----\> 0.1 ml/kg
Study: NCT03511833
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---\> 0.02ml/kg
Study: NCT01245205
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04648540
Drug: Dexmedetomidine 0.5 mic/kg/h
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours
Study: NCT00792701
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00792701
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00553930
Drug: Pegylated interferon alfa-2a and Ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
Study: NCT00553930
Drug: Pegylated interferon alfa 2a and Ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of \>= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
Study: NCT02291679
Drug: Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00032279
Drug: Visilizumab
Normalized name: Visilizumab
DrugBank: Visilizumab (DB12053)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01962285
Drug: propofol targel controlled infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
Study: NCT00456833
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02048072
Drug: Gilenya
Normalized name: Gilenya
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Autonomic testing during first dose administration of Gilenya.
Study: NCT03153579
Drug: LSD
Normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysergic Acid Diethylamide~200ug per os, single dose
Study: NCT01509911
Drug: TL-118
Normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
Study: NCT01509911
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monthly cycles of 3 weekly treatments a month and one week off of treatment
Study: NCT01068158
Drug: 0.5% Ivermectin Cream
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
Study: NCT00698334
Drug: INH, Rifampicin, Ethambutol and Pyrazinamide
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
Study: NCT00364741
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During and 2 hours after surgery
Study: NCT03948191
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
Study: NCT03948191
Drug: 99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
Normalized name: (99Tc)pertechnetate
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
Study: NCT03620253
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Study: NCT02276222
Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer
Normalized name: clozapine
DrugBank: SUN-101 (DB17238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
Study: NCT03076099
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
Study: NCT00377325
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/Kg/day; daily; liquid form; 6 months
Study: NCT00568048
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
Study: NCT01963325
Drug: S-1 plus Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
Study: NCT03372122
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A cloth to cleanse and disinfect the skin
Study: NCT02813070
Drug: [18F] Flutemetamol
DrugBank: Flutemetamol (18F) (DB09151)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PET brain imaging and Magnetic resonance brain imaging
Study: NCT01379170
Drug: Euthyrox (levothyroxine)
Normalized name: levothyroxine Oral Tablet [Euthyrox]
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
Study: NCT01012232
Drug: 20 mL ropivacaine 5 mg/mL
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01012232
Drug: 10 mL ropivacaine 10 mg/mL
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02617017
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
Study: NCT03752216
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria.
Study: NCT00983086
Drug: Flavanones of orange juice
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
Study: NCT01951625
Drug: Vericiguat (BAY1021189) (1.25 mg)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.25 mg BAY1021189 tablets
Study: NCT01951625
Drug: Vericiguat (BAY1021189) (5 mg)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg BAY1021189 tablets
Study: NCT00642187
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00817362
Drug: IPI-504
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IPI-504 IV infusion 300 mg/m2
Study: NCT00817362
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
Study: NCT00436293
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m²
Study: NCT01592370
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered PO
Study: NCT01592370
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered PO and by IV infusion
Study: NCT00436293
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m²
Study: NCT03285906
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy Apatinib：500 mg，po，qd
Study: NCT03395756
Drug: Depot-Medroxyprogestereone Acetate
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 150 mg intramuscular depot medroxyprogesterone acetate
Study: NCT01395641
Drug: gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
Study: NCT00425113
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02598505
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00019227
Drug: pentetic acid calcium
Normalized name: Pentetic acid
DrugBank: Pentetic acid (DB14007)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00830960
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral, daily, 90 days
Study: NCT00830960
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral, daily, 90 days
Study: NCT02823080
Drug: Cetrorelix
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
Study: NCT03351439
Drug: Zopiclone
Normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
Study: NCT03351439
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
Study: NCT03351439
Drug: Celebrex
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
Study: NCT03351439
Drug: Percocet
Normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT03217448
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
Study: NCT03217448
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
Study: NCT00550485
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: escitalopram 4 mg
Study: NCT03351439
Drug: Naprosyn
Normalized name: Naprosyn
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT01530555
Drug: Rabbit ATG, Thymoglobuline (Genzyme)
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months
Study: NCT04461028
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
Study: NCT04461028
Drug: Bupivacaine with Dexamethasone Solution
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.